|Faculty Roundtable on CAR T-cell Therapies, Bispecific Antibodies & Antibody-Drug Conjugates in FL
CME, CPE, CNE
Loretta J. Nastoupil, MD and Catherine S. Diefenbach, MD
|Release Date: March 09, 2023
Expiration Date: March 09, 2024
Although follicular lymphoma (FL) often responds well to initial therapy, many patients will relapse, and a considerable proportion of patients experience disease progression within 24 months. In this activity, Drs. Nastoupil and Diefenbach address the recent advances in FL-directed CAR T-cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). They will also discuss safety and efficacy data from ongoing clinical trials, and how to incorporate recently approved and emerging novel targeted therapies into individualized treatment strategies.Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
|Begin, Earn CreditView Only, No Credit|